NCT00875979 (Clinical Trial/ Ado-Trastuzumab Emtansine)

Study Title
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab (NCT00875979)

Trial Description
This was a multi-institutional, multinational, open-label, single-arm Phase Ib/II study designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) administered by intravenous (IV) infusion in combination with  pertuzumab (Perjeta®; Genentech, Inc.) in patients with human epidermal growth factor receptor-2 (HER2)-positive locally advanced or metastatic breast cancer who had previously received trastuzumab.

This trial is sponsored by F. Hoffmann-La Roche. [1]

Study Data

  • Condition: Metastatic Breast Cancer
  • Interventions:
  • Phase: I & II
  • Enrollment: 67
  • Start: May 2009
  • Completion: August 2011
  • Last verified: December 2013

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 28, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.